Though some with chronic lymphocytic leukemia (CLL) may have limited access to clinical trials at expert centers, telemedicine may change access for some patients. Watch as Dr. John Pagel shares how telemedicine might improve CLL clinical trial options.
Will Telemedicine Activate More Remote Tools to Manage CLL?
There is a lot of attention being paid to clinical trials and progress, and so how might telemedicine impact clinical trials when it comes to CLL therapy?
Dr. John Pagel:
Well, I want to first tell the audience that clinical trials are critically important for many patients who have CLL. Clinical trials are really an opportunity to get something that’s better than the standard of care most often, or at least just as good and has the promise again, to be better. We have advanced major new paradigm changing therapies over the last many years through clinical trials, and now we’re looking at really exciting things like bispecific antibodies, newer generations of these targeted therapies that are better tolerated and perhaps even more active in resistant patients. And even as we talked about CAR T-cell therapies, those are all only available through clinical trials, and then that’ll continue to evolve and go on as well.
I would encourage patients to think about clinical trials, and because of telemedicine, now we’re going to be able to reach to other patients who are further away from an expert, perhaps where clinical trials are only available, and they can be then involved in one of those opportunities. Telemedicine, I hope, and I believe, will be a major advance for getting the cutting-edge, best therapies for patients who might be very far away from a very important expert center.
As telemedicine has grown in the management of chronic lymphocytic leukemia (CLL) care, will its use bring other remote tools into patient care? Watch as CLL expert Dr. John Pagel explains.
Dr. Pagel, there are tools out there like video otoscopes, electronic stethoscopes, thermoscopes, retinal imaging systems, will CLL patients be able to have access to those tools for themselves one day, and on that note, what are the tools you believe will impact the future of CLL care?
Dr. John Pagel:
Yeah, in fact, that’s really where we’re going. We do stuff like that already through the hospital. As you may know, as an example, if someone comes in with a cardiac condition, they need to be monitored remotely, they can’t stay in the hospital indefinitely we need to kind of know what’s happening, perhaps as an example with their heart rhythm. So they actually have tools where they can wear a little monitor even on their wrist that communicates with the doctor. So the doctor can see even in real time what’s happening with that individual patient.
These types of tools are the future, and we’re not going away from them, we’re embracing them. We’re not there yet for routine standard care, especially in CLL but they will be simple things like heart rate, blood pressure measurements that are very simple and easy to do that not only are able to be read by the patient, but actually again, from a remote standpoint, be electronically downloaded and delivered to the physician, real time. That’s going to be important. And actually, I believe that we’ll even add advances for that in the blood work or other approaches in the near future. So just stay tuned we’re just scratching the surface there.
Okay, so you’ve heard it here first from Dr. Pagel, stay tuned on this.
What are some of the barriers to clinical trial participation? What is a virtual clinical trial? Should my doctor be speaking to me about my clinical trial options? Dana Dornsife, founder of Lazarex Cancer Foundation, speaks to the key barriers in trials and how COVID-19 has really opened the door for a lot of opportunity to engage with patients around clinical trials.